Cervical cancer: chemo added to carbon-ion radiotherapy tied to longer survival

  • Okonogi N & al.
  • Cancer Med
  • 31 Dec 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Carbon-ion radiotherapy (C-ion RT) with concurrent chemotherapy (chemotherapy-C-ion RT) is tied to longer survival vs C‐ion RT in patients with adenocarcinoma of the uterine cervix.

Why this matters

  • Long-term efficacy of chemotherapy-C-ion RT is unknown.

Study design

  • Pooled analysis of 82 patients with stage IIB-IVA adenocarcinoma of the uterine cervix who underwent C-ion RT alone or chemotherapy-C-ion RT.
  • Patients received 74.4 Gy of C-ion radiation with or without weekly cisplatin.
  • Funding: None disclosed.

Key results

  • The matched cohort contained 26 patients who underwent C‐ion RT and 26 who underwent chemotherapy‐C‐ion RT.
  • Median follow‐up duration was 34 months.
  • 5‐year OS rate was significantly higher in the chemotherapy‐C‐ion RT group vs the C‐ion RT group (72% vs 46%; P=.041).
  • The 5‐year distant metastatic‐free survival rate was also significantly higher in the chemotherapy‐C‐ion RT group vs the C‐ion RT group (66% vs 41%; P=.048).
  • The incidence of grade ≥3 late toxicities was similar between the 2 groups (P=.602).

Limitations

  • Retrospective design.